Pfizer's new obesity shot shows promise in first human tests
NCT ID NCT07022977
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a new weekly injection called MET233 in 144 otherwise healthy adults with overweight or obesity. The main goal was to check safety and how the drug moves through the body. Researchers also looked at different dosing schedules over several weeks. Since this is a Phase 1 study, it is too soon to know if MET233 will help with weight loss.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MET233 (a biologic drug given as a weekly injection)
- What this could lead to
- If it works, this could point toward a new treatment for weight management.
- What could go wrong
- This is a very early Phase 1 trial focused on safety, not weight loss. The drug may not work or could have side effects. Results may not lead to a marketed treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY AND OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Altasciences Clinical Los Angeles, Inc.
Cypress, California, 90630, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can timing your carbs tame metabolic risk?
- Home visits may boost heart health for pregnant women in nigeria
- Could a diabetes drug protect obese Teens' hearts?
- Could a biweekly shot rival weekly Weight-Loss drugs?
- Scientists investigate why some bodies fight weight change
- Fasting test may unlock personalized obesity treatment